Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Comparing Patients After ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2007 by Hadassah Medical Organization.
Recruitment status was:  Not yet recruiting
Information provided by:
Hadassah Medical Organization Identifier:
First received: May 24, 2007
Last updated: NA
Last verified: May 2007
History: No changes posted
The purpose of this study is to see whether patients undergoing ESWL, for upper tract urinary stones between 1.5-2.0cm, may be treated by expulsion therapy(Tamsulosin) instead of inserting ureteral stents .

Condition Intervention Phase
Upper Tract Ureterolithiasis
Drug: Tamsulosin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Phase II Study Comparing Two Groups of Patients Undergoing ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • stone status at 3 month .
  • stone free


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patients above 18 yrs of age.
  • Single urolithiasis up to 2 cm.
  • Kidney/ureters that haven't undergone previous ESWL or stent insertion.
  • Normal renal function (creatinine below 100mmo1/1).
  • Sterile urine culture.
  • Normal CBC, blood electrolytes and coagulation studies.
  • Radioopaque stones.

Exclusion Criteria:

  • More than one stone per kidney unit.
  • Patients receiving steroids, NSAIDS, calcium channel blockers or alpha blockers on a regular basis.
  • Anatomical anomalies or uromechanical obstruction.
  • Single kidney.
  • Cystinuria.
  • Soldiers or pregnant women.
  • Patients under 18 year
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00478998

Contact: Mordechai Duvdevani, MD 0508946816
Contact: Shilo Rosenberg, MD 0508946036

Hadassah Medical Organization Not yet recruiting
Jerusalem, Israel, 91120
Contact: Mordechai Duvdevani, MD    0508946816   
Principal Investigator: Mordechai Duvdevani, MD         
Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Mordechai Duvdevani, MD Hadassah Medical Organization
  More Information Identifier: NCT00478998     History of Changes
Other Study ID Numbers: 890pal- HMO-CTIL
Study First Received: May 24, 2007
Last Updated: May 24, 2007

Keywords provided by Hadassah Medical Organization:
expulsion therapy

Additional relevant MeSH terms:
Ureteral Calculi
Ureteral Diseases
Urologic Diseases
Urinary Calculi
Pathological Conditions, Anatomical
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents processed this record on May 25, 2017